Pharmaceutical News

RSS

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.

19 Apr 2010

FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the Company has received U.S. Food and Drug Administration (FDA) approval to market mesna injection (mesna), a prophylactic agent used to reduce the incidence of hemorrhagic cystitis caused by ifosfamide chemotherapy.

19 Apr 2010

Study finds impact of free prescriptions on dispensing rates minimal

The overall impact of free prescriptions on dispensing rates in Wales has been minimal according to research conducted by academics at the University of Glamorgan in collaboration with colleagues at Cardiff and Bangor Universities.

19 Apr 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.

19 Apr 2010

NDA for Cadence Pharmaceuticals' OFIRMEV injection to be re-submitted to FDA

Cadence Pharmaceuticals, Inc. announced today that, based on feedback received during a meeting with the U.S. Food and Drug Administration on April 16, 2010, it plans to re-submit a New Drug Application for its investigational product candidate, OFIRMEV (acetaminophen) injection, within the next 30 days.

19 Apr 2010

Mylan Pharmaceuticals introduces 50 mg and 200 mg Clozapine Tablets USP

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Clozapine Tablets USP, 50 mg and 200 mg.

19 Apr 2010

Investment report on Generex Biotechnology from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

19 Apr 2010

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.

19 Apr 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics, Inc. today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

Study shows long-term effect of vitamins and calcium supplements in breast cancer reduction

Vitamins and calcium supplements appear to reduce the risk of breast cancer, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010.

19 Apr 2010

Pre-clinical data on MM-121 and MM-111 to be presented at AACR 2010

Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.

17 Apr 2010

Honey beneficial for treatment of fungating tumor wounds

Surviving cancer is physically and emotionally exhausting. But for many patients, beating the disease itself is just the first hurdle. A second ordeal comes from living with the fungating tumor wounds that accompany various cancers. Aside from the pain they inflict, these wounds often emit a strong and offensive odor. Not only does going into public become potentially embarrassing, but it also can be extremely depressing when even close family members are repulsed by the smell.

17 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

2010 to be an active year for new drug applications, says Fitch Ratings

Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.

17 Apr 2010

MEDIHONEY dressings serve as low-cost method for treating wounds in indigent patients

Using a particular brand of medical honey dressing may be a safe, effective and low-cost method of treating chronic, non-healing wounds in indigent patients, according to a poster presented at the Symposium on Advanced Wound Care and the Wound Healing Society, an international conference drawing clinicians from all over the globe, which was held April 17-20 in Orlando.

17 Apr 2010

MEDIHONEY dressings effective in treating chronic wounds in children

Chronic, non-healing wounds can be a serious problem for children as many currently available treatment modalities can be too harsh or toxic. At the 2010 Symposium on Advanced Wound Care (SAWC) and the Wound Healing Society (WHS), an international conference drawing clinicians from all over the globe which was held April 17-20 in Orlando, two clinicians presented case series illustrating the benefits of MEDIHONEY® dressings for this challenging patient population.

17 Apr 2010

NVIC participates in NVAC-sponsored meeting to discuss the U.S. vaccine safety system

The National Vaccine Information Center participated in a meeting sponsored by the federal National Vaccine Advisory Committee and facilitated by The Keystone Center April 11-13 in Salt Lake City to discuss strengthening the U.S. vaccine safety system.

17 Apr 2010

Global Leaders Institute to host VacChina 2010 Vaccine Development Summit

Hosted by Global Leaders Institute, "VacChina 2010", a Vaccine Development Summit to be held from September 15-16, 2010, will bring together the world's major vaccine players and their respective senior level representatives to Shanghai, the heart of China's biopharmaceutical innovation.

17 Apr 2010